Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday.

Other analysts also recently issued reports about the company. Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, June 17th. Maxim Group restated a “buy” rating and set a $7.00 price target on shares of Keryx Biopharmaceuticals in a research note on Monday, May 1st. ValuEngine lowered Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a research note on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $8.27.

Keryx Biopharmaceuticals (NASDAQ KERX) traded up 1.56% during mid-day trading on Wednesday, hitting $7.18. 278,279 shares of the stock were exchanged. Keryx Biopharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.38. The stock’s market cap is $778.79 million. The stock has a 50 day moving average of $6.98 and a 200-day moving average of $6.05.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.03. Keryx Biopharmaceuticals had a negative return on equity of 1,122.28% and a negative net margin of 387.12%. The business had revenue of $11.82 million for the quarter, compared to the consensus estimate of $10.19 million. During the same quarter last year, the business posted ($0.39) earnings per share. The firm’s revenue for the quarter was up 73.2% compared to the same quarter last year. Equities analysts predict that Keryx Biopharmaceuticals will post ($0.69) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/07/21/keryx-biopharmaceuticals-inc-nasdaqkerx-stock-rating-lowered-by-bidaskclub.html.

Institutional investors have recently bought and sold shares of the stock. Stifel Financial Corp raised its position in Keryx Biopharmaceuticals by 11.5% in the first quarter. Stifel Financial Corp now owns 33,736 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 3,478 shares during the period. Lincoln Capital Corp bought a new position in Keryx Biopharmaceuticals during the fourth quarter valued at about $158,000. Rice Hall James & Associates LLC raised its position in Keryx Biopharmaceuticals by 3.0% in the first quarter. Rice Hall James & Associates LLC now owns 1,340,649 shares of the biopharmaceutical company’s stock valued at $8,258,000 after buying an additional 39,656 shares during the period. Janney Montgomery Scott LLC raised its position in Keryx Biopharmaceuticals by 29.1% in the first quarter. Janney Montgomery Scott LLC now owns 66,565 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 15,000 shares during the period. Finally, Bank of Montreal Can bought a new position in Keryx Biopharmaceuticals during the first quarter valued at about $434,000. Institutional investors own 62.27% of the company’s stock.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.